Tsuyoshi Kaneko, MD

Tsuyoshi Kaneko, MD

Chief, Section of Cardiac Surgery
John M. Shoenberg Chair in Cardiovascular Disease

Expertise

Specialty Areas

  • Minimally invasive valve surgery
  • Complex valve surgery
  • Transcatheter valve therapies

Common Procedures

  • Mitral valve repair and replacement
  • Aortic valve repair and replacement
  • Ross procedure
  • Aortic root replacement
  • Ascending aortic replacement
  • Transcatheter aortic valve replacement (TAVR)
  • Transcatheter mitral valve replacement
  • Transcatheter tricuspid valve replacement
  • Transcatheter mitral/tricuspid valve repair (TEER)

Common Diagnoses Treated

  • Aortic stenosis and regurgitation
  • Mitral stenosis and regurgitation
  • Tricuspid regurgitation
  • Aortic aneurysm
  • Atrial fibrilation
  • Coronary artery disease
  • Endocarditis
  • Valvular heart diseases
  • Prolapse
  • Hypertrophic cardiomyopathy
  • Marfan syndrome
  • Pericardial disease
Education

Board Certifications

General Surgery

Cardiothoracic Surgery

Degrees

Medical School: Keio University School of Medicine, Tokyo, Japan, 2002

Residency

General Surgery Residency & Cardiac Surgery Residency, Keio University School of Medicine, Tokyo, Japan, 2002-2006

General Surgery Internship, New York Medical College, Bronx Program, New York, NY, 2006-2007

General Surgery Residency, University of Texas at Houston, Houston, TX, 2007-2011

Cardiothoracic Surgery Residency, Brigham and Women’s Hospital, Boston, MA, 2011-2013

Fellowship

Transcatheter Fellowship, Brigham and Women’s Hospital, Boston, MA, 2013-2014

Aortic Surgery Fellowship, Duke University Hospital, Durham, NC, 2014

Professional Memberships

Society of Thoracic Surgeons

American Association of Thoracic Surgery

Southern Thoracic Surgery Association

American College of Surgeons

American College of Cardiology

American Heart Association

Awards and Honors

  • Current Chair of Research and Publication Committee of the American College of Cardiology/the Society of Thoracic Surgeons TVT NCDR Registry
  • Current Vice Chair of the Workforce in Innovation and New Technology Committee for the Society of Thoracic Surgeons
  • Current Chair of the Michael Davidson Fellowship for Thoracic Surgery Foundation
  • 2022, Castle Connolly Top Doctors (Boston Magazine)
  • 2022, William McGoon Award, Best Teaching Award, Thoracic Surgery Resident Association (Teaching)
  • 2022, William Clark Award for Best Presentation (Senior Author), Society for Thoracic Surgeons (Academic)
  • 2020, Best Poster Presentation (Senior Author), Society of Thoracic Surgeons
  • 2019, C. Walton Lillehei Award, Best Presentation (Senior Author), American Association of Thoracic Surgery
  • 2019, Maxwell Chamberlain Award, Best Presentation (Senior Author), Society of Thoracic Surgeons
  • 2018, Emerging Faculty Award, American College of Cardiology
  • 2018, Best Presentation by a Senior Author, Massachusetts Chapter of the American College of Surgeons
  • 2017, 2019, Nominee, Excellence in Mentoring Award, Harvard Medical School
  • 2013, 2017, John J. Collins Teaching Award, Brigham and Women’s Hospital
  • 2013, Best Presentation Award, Massachusetts Chapter of the American College of Surgeons
  • 2012, Best Aortic Presentation Award, International Society of Minimally Invasive Cardiothoracic Surgery
  • 2011, Best Chief Resident Award, University of Texas at Houston
  • 2010, Raleigh Ross Scholarship Award, Texas Medical Society
  • 2007, Best Intern Award, New York Medical College

Editorial Activities

Ad hoc reviewer for the following publications:

  • New England Journal of Medicine
  • Journal of American Medical Association
  • Cochrane Database of Systematic Reviews
  • Circulation
  • Circulation: Cardiovascular Interventions
  • Journal of American College of Cardiology
  • Journal of American College of Cardiology- Interventions
  • Journal of American College of Cardiology- Cardiovascular Imaging
  • Journal of American College of Cardiology- Case Reports
  • Journal of Thoracic and Cardiovascular Surgery
  • Seminars in Thoracic and Cardiovascular Surgery
  • Operative Techniques in Thoracic and Cardiovascular Surgery
  • American Heart Journal
  • Heart
  • Annals of Thoracic Surgery
  • Annals of Surgery
  • European Journal of Cardiothoracic Surgery
  • Circulation Journal
  • Journal of Surgical Education
  • Journal of Interventional Cardiology
  • Clinical Cardiology
  • Journal of Intensive Critical Care
  • Vascular and Endovascular Surgery
  • Aorta
  • Structural Heart: The Journal of the Heart Team
Research

Areas of Research Interest

Surgical and transcatheter valve surgery using large database outcomes studies

Innovations

  • 2020, along with interventional cardiology at Brigham and Women’s Hospital, started the LANPOON procedure, which lacerates the mitral leaflet at the time of TMVR to avoid left ventricular outflow tract (LVOT) obstruction
  • 2019, along with interventional cardiology at Brigham and Women’s Hospital, started the BASILICA procedure, which lacerates the leaflet at the time of TAVR to avoid coronary obstruction
  • 2018, along with interventional cardiology at Brigham and Women’s Hospital, used access via the femoral vein to cross from IVC to aorta to perform TAVR in patients with no peripheral vascular access
  • 2018, along with interventional cardiology at Brigham and Women’s Hospital, used tricuspid clip in a tricuspid valve to reduce the amount of tricuspid regurgitation
  • 2018, along with the vascular surgery team at Brigham and Women’s Hospital, started using snorkeling stents for TEVAR to allow a proximal landing zone while preventing stroke
  • 2018, performed one of the first TAVRs in a patient with aortic insufficiency in left ventricular assist device in New England in a patient with prohibitive risk for surgery
  • 2018, along with the interventional cardiology team at Brigham and Women’s Hospital, started using the embolic protection device to decrease the incidence of stroke during TAVR
  • 2017, in a joint effort with Alice Kim, MD, started the cardiac surgery/structural heart clinic at Kent Hospital in Rhode Island
  • 2017, led the team that initiated one of the first ERAS programs for cardiac surgery at Brigham and Women’s Hospital and disseminated protocol to multiple institutions
  • 2017, initiated and is one of the first in the U.S. to perform transatrial TMVR via right thoracotomy
  • 2017, initiated one of the first percutaneous transsubclavian TAVRs in the country using a balloon expanding valve
  • 2016, started the first ascending aortic stent grafting program in the northeast region using transaxillary technique
  • 2016, initiated the institutional percutaneous TEVAR using Perclose devices
  • 2016, initiated one of the first conscious sedation alternative TAVRs in the country using regional block
  • 2016, along with the interventional cardiology team, initiated TMVR via the transseptal approach
  • 2016, along with the interventional cardiology team, promoted the introduction of the fast track for transfemoral TAVR, resulting in reduced hospital length-of-stay and shorter ICU stay
  • 2015, initiated fast track for surgical transcatheter aortic valve replacement (TAVR), resulting in reduced hospital length-of-stay and shorter ICU stay
  • 2015, initiated the monitoring of evoked potentials during thoracoabdominal aortic aneurysm surgery, which is now the gold standard at Brigham and Women’s Hospital
  • 2015, extended the use of the hybrid procedure in aortic surgery using open and endovascular technique in the hybrid OR

Clinical Trials

2015

  • Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation, Evalve (NCT01626079). Sub-PI ($14, 749)
    • The overall goal is to confirm the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe or severe functional mitral regurgitation (FMR) in Symptomatic Heart Failure Subjects who are treated per standard of care and who have been determined by the site’s local heart team as not appropriate for mitral valve surgery.
  • The PARTNER Trial: Placement of AoRTic TraNscathetER Valves, Edwards Lifesciences (NCT00530894), Site PI
    • The goal of this grant is to determine the safety and effectiveness of the Edwards SAPIEN transcatheter heart valve and delivery systems which are intended for use in patients with high risk and inoperable symptomatic, calcific, severe aortic stenosis.
  • The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves, Edwards Lifesciences (NCT01314313), Site PI: $1,133,900
    • The goal of this grant is to determine the safety and effectiveness of the Edwards SAPIEN XT and the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis.

2016

  • The PARTNER II Trial: S3iCAP, Edwards Lifesciences (NCT02687035), Site PI
    • This multi-center, single arm registry will provide continued access of the Edwards SAPIEN 3 Transcatheter Heart Valve and delivery systems to severe aortic stenosis patients at intermediate risk for standard aortic valve replacement. Patient data will be entered into the TVT Registry (TVTR) from screening through 1 year including the collection of 5-year follow-up through CMS.

2017

  • The PARTNER 3 – Trial – The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients With Aortic Stenosis (P3), Edwards Lifesciences (NCT02675114), Site PI
    • A prospective, randomized, controlled, multi-center study to establish the safety and effectiveness of the SAPIEN 3 Transcatheter Heart Valve in low-risk patients who have severe, calcific, aortic stenosis requiring aortic valve replacement.
  • Mitral Implantation of TRAnscatheter vaLves (MITRAL), Edwards Lifesciences (NCT02370511), Co-PI; Site PI: Pinah Shah, M.D.
    • The safety and feasibility of the SAPIEN XTTM Transcatheter Heart Valve with NovaFlex and Ascendra delivery systems and SAPIEN 3 with commander delivery system in patients with symptomatic severe calcific mitral valve disease with severe mitral annular calcification and patients with failing mitral surgical rings or bioprostheses who are not candidates for mitral valve surgery.
  • Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveiLlance for Patients with AsYmptomatic Severe Aortic Stenosis (EARLY TAVR), Edwards Lifesciences (NCT03042104), Site PI
    • This clinical trial is a prospective, randomized, controlled, multi-center study. Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 THV or clinical surveillance.
  • Peripheral versus Central Access for Alternative Access Transcatheter Aortic Valve Replacement (TAVR), Watkins’s Investigator Grant, PI: $60,000
    • This study is to identify the best option for alternative access TAVR, by comparing outcomes after central (trans-aortic, trans-apical) vs. peripheral arterial access (transcarotid, trans-subclavian) for TAVR in patients who are not candidates for transfemoral access using TVT registry.

2018

  • Transcatheter Mitral Valve Replacement with the Medtronic Intrepid™ TMVR System in Patients with Severe Symptomatic Mitral Regurgitation (APOLLO), Medtronic (NCT03242642), Site PI
    • Multi-center, global, prospective, randomized, interventional, pre-market trial with two subject groups: the randomized group will be randomized on 1:1 basis to either the study device or to conventional mitral valve surgery. Subjects in the single-arm group will receive the study device.
  • Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE), Edwards Lifesciences (NCT03016975), Site PI
    • The ACTIVE Trial is a prospective, randomized, multicenter trial. Patients with clinically significant functional mitral regurgitation will be randomized 2:1 to receive either transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT) or GDMT alone. Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 5 years.

2019

  • Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial (CLASP IID/IIF), Edwards Lifesciences (NCT03706833), Site PI
    • A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR). Patients will be seen for follow-up visits at discharge, 30 days, 6 months, and annually through 5 years.
  • ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement, Boston Scientific (NCT03735667), Site PI
    • To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
  • AltaValve Early Feasibility Study Protocol, 4C Medical (NCT03997305), Site PI
    • Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open heart surgery.

2020

  • TRILUMINATE Pivotal Trial, Abbott Medical Devices (NCT03904147), Site PI
    • The primary objective of this trial is to demonstrate the safety and effectiveness of the TriClip device in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (TriClip device) to Control (Medical Therapy).
  • MitraClip REPAIR MR Study, Abbott Medical Devices (NCT04198870), Site PI
    • The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus open surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
  • TRISCEND Early Feasibility Study, Edwards Lifesciences (NCT04221490), Site PI
    • The study is a multicenter, prospective, single arm study to evaluate the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System.
  • TRISCEND II Pivotal Trial, Edwards Lifesciences (NCT04482062), Site PI
    • The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the EVOQUE System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.

2021

  • REPAIR-MR Trial, Abbott Medical Devices (NCT04198870), Site PI
    • The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.

2022

  • PRIMARY Trial, CTSN (NIH Sponsor), Site PI
    • This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.

Financial Disclosures

Consultant: Edwards Lifesciences, Medtronic, Abbot

Publications

Click here for list of publications by Dr. Kaneko on PubMed
Locations

Hospital Affiliations

Barnes-Jewish Hospital

Patients Seen At

Center for Advanced Medicine
Heart and Vascular Center
4921 Parkview Place, Suite A, Floor 8
St. Louis, MO 63110
314-362-7260

News and Stories

2022

  • Interviewee, Cardiovascular News, “Large-Scale Analysis Points Toward Positive Outcomes in Bicuspid Aortic Stenosis Patients Receiving Surgery”
  • Interviewee, TCTMD, “Bicuspid SAVR Outcomes Meet or Beet Tricuspid in STS Database”

2021

  • Haymarket Physician Training Series “Bicuspid Valve Updates- TAVR vs. SAVR”
  • Interviewee, TCTMD, “Valve-in-Valve TAVI Bests Redo SAVR in Short Term”
  • Interviewee, Medscape, “Repeat TAVR Central to Aortic Valve Disease Lifetime Strategy
  • Interviewee, Cardiovascular Business, “Cutting-Edge Findings Shine New Light on Mitral Valve Surgery After Failed TEER”

2020

  • Moderator, CTSNet roundtable, “Surgical and Transcatheter Management of MR: Competing or Complementary?”
  • Interviewee, WPTV News, “Innovations in Cardiac Care”
  • Interviewee, Brigham Bulletin, “Patient Experience After TAVR”
  • Interviewee, Practical Cardiology, “Gender Differences in Mitral Valve Reoperation”
  • Interviewee, Practical Cardiology, “ACC House Call on Late-Breaking TAVR Data”
  • Interviewee, HCP Live, “Discussion on TAVR after Low-risk Approval”
  • Podcast Guest, MD Magazine Podcast, “Current Updates on TAVR”

2019

  • Panelist, CTSNet roundtable, “Surgical Training for Transcatheter Aortic Valve Replacement”
  • Moderator, CTSNet roundtable, “The Horizon of Transcatheter Mitral Therapies: How Should the Surgeons Prepare?”
  • Speaker, CTSNet basic skills video, “Perclose Suture Mediated Closure Technique”
  • Interviewee, CTSNet, “Feature Profile and Interview with Tsuyoshi Kaneko, MD”
  • Interviewee, Harvard Heart Letter, “Transcatheter Aortic Valve Replacement”
  • Interviewee, Harvard Health Publishing, Harvard Health Blog, “MitraClip: Valve Repair Device Offers New Treatment Option for Some With Severe Mitral Regurgitation”
  • Interviewee, TCTMD, “Surgical Risk Should Be ‘Off The Table’ When Deciding on Eligibility for TAVR”
  • Interviewee, TCTMD, “Surgical Bailout Rarely Needed Though Can Saves Lives: TVT Registry”
  • Interviewee, TCTMD, “TAVR Outcomes Dependent on SAVR Hospital Volumes”
  • Podcast Guest, JAMA Cardiology Podcast, “Utility of 90-Day vs. 30-Day Mortality Quality Metrics for Aortic Valve Replacement Outcomes”
  • Author, Physician Weekly Cardiology, “Is There a July Effect in July Effect?”
  • Guest Reviewer, Healthcare Monitor, “Medical Update on Aortic Stenosis”

2018

  • Co-author, Edwards Lifesciences, “Subclavian/Axillary TAVR Protocol Guide”
  • Moderator, CTSNet roundtable discussion, “Transcatheter Mitral Valve Therapies: What is the Future for the Surgeons?”
  • Interviewee, Harvard Heart Letter, “Mitral Valve Treatment”
  • Author, CTSNet Cardiac Surgery Essentials Video, “Percutaneous Vascular Closure
  • Interviewee, Medpage, “Utility of 30-days and 90-days Morality in TAVR”

2016

  • Interviewee, BWH Heart & Vascular Center Update, “Valve Repair”

2015

  • Interviewee, Harvard Heart Letter, “Aortic Valve Replacement”

2013

  • Co-Author, “Road to Clinical Training in the United States”

2010

  • Co-author, “Passport for Clinical Training in the United States”
Contact

To request an appointment with Dr. Kaneko, please call 314-362-7260.